{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:23:32Z","timestamp":1792304612156,"version":"4.4.0"},"reference-count":30,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The Papanicolaou (Pap) test has indisputably decreased cervical cancer mortality, as rates have declined by up to 80% in the United States since its implementation. However, the Pap test is considered less sensitive for detecting glandular lesions than for detecting those of squamous origin. Some studies have even suggested an increasing incidence of cervical adenocarcinoma, which may be a consequence of a relatively reduced ability to detect glandular lesions with cervical cancer screening techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the detection rate of glandular lesions with screening techniques currently used for cervical cancer screening and to provide insight as to which techniques are most efficacious in our study population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We retrospectively reviewed any available cytology, human papillomavirus (HPV), and histologic malignancy data in patients diagnosed with adenocarcinoma in situ and adenocarcinoma from 2 geographically and socioeconomically disparate hospital systems. Identified patients having had a negative\/unsatisfactory Pap test within 5 years of adenocarcinoma in situ or adenocarcinoma tissue diagnosis were considered Pap test screening failures. Patients with negative HPV tests on cytology samples were considered HPV screening failures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred thirty cases were identified (age range, 22\u201393 years); 39 (30%) had no Pap history in our files. Eight of 91 remaining cases (8.8%) were screening failures. The detected sensitivity for identifying adenocarcinoma in situ\/adenocarcinoma in this study was 91.2% by cytology alone and 92.3% when incorporating HPV testing. The most common cytologic diagnosis was atypical glandular cells (25 cases), and those diagnosed with adenocarcinoma were 7.4 years older than those diagnosed with adenocarcinoma in situ (50.3 versus 42.9 years). Nine of 24 HPV-tested cases (37.5%) were called atypical squamous cell of undetermined significance on cytology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results highlight the importance of combined Pap and HPV cotesting. Although the number of cases identified is relatively small, our data suggest screening for squamous lesions facilitates the recognition of glandular lesions in the cervix. Additionally, increased use of combined Pap and HPV cotesting may decrease detection failure rates with regard to glandular lesions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2014-0633-oa","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T16:58:17Z","timestamp":1431017897000},"page":"1431-1436","source":"Crossref","is-referenced-by-count":25,"title":["Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions"],"prefix":"10.5858","volume":"139","author":[{"given":"Ross A.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina R.","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberlee C.","family":"Tams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thrall","sequence":"additional","affiliation":[{"name":"From the University of South Dakota Pathology Residency Program, Sioux Falls (Dr Miller); the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Drs Mody and Thrall); and the Sanford Health Pathology Clinic, University of South Dakota Medical Center, Sioux Falls (Dr Tams). Dr Miller is now with the Department of Pathology and Genomic Medicine, Houston Method"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2015,5,7]]},"reference":[{"issue":"3","key":"2020081220292063100_i1543-2165-139-11-1431-b01","doi-asserted-by":"crossref","first-page":"217","DOI":"10.18553\/jmcp.2010.16.3.217","article-title":"Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types","volume":"16","author":"Armstrong","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"2020081220292063100_i1543-2165-139-11-1431-b02","unstructured":"US Cancer Statistics Working Group. United States Cancer Statistics: 1999\u20132007 Incidence and Mortality Web-Based Report. Atlanta, GA: Dept of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute;2010."},{"key":"2020081220292063100_i1543-2165-139-11-1431-b03","article-title":"SEER Cancer Statistics Review, 1975\u20132011. National Cancer Institute Web site","author":"Howlader","year":"2014"},{"issue":"3","key":"2020081220292063100_i1543-2165-139-11-1431-b04","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mdp471","article-title":"European Guidelines for Quality Assurance in Cervical Cancer Screening: second edition\u2014summary document","volume":"21","author":"Arbyn","year":"2010","journal-title":"Ann Oncol"},{"issue":"10","key":"2020081220292063100_i1543-2165-139-11-1431-b05","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2283::AID-CNCR12>3.0.CO;2-D","article-title":"Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan","volume":"88","author":"Sung","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"2020081220292063100_i1543-2165-139-11-1431-b06","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cncr.20877","article-title":"Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival","volume":"103","author":"Sherman","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"2020081220292063100_i1543-2165-139-11-1431-b07","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1012761717028","article-title":"Age-incidence relationships and time trends in cervical cancer in Sweden","volume":"17","author":"Hemminki","year":"2001","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"2020081220292063100_i1543-2165-139-11-1431-b08","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/gyno.2000.5826","article-title":"The rising incidence of adenocarcinomass relative to squamous cell carcinoma of the uterine cervix in the United States, a 24-year population based-study","volume":"78","author":"Smith","year":"2000","journal-title":"Gynecol Oncol"},{"key":"2020081220292063100_i1543-2165-139-11-1431-b09","unstructured":"DeMay M. The Art and Science of Cytopathology. 2nd ed. Chicago, IL: American Society for Clinical Pathology Press;2012."},{"key":"2020081220292063100_i1543-2165-139-11-1431-b10","unstructured":"Mody DR. Diagnostic Pathology: Cytopathology. Altona, MB: Amirsys Publishing;2014."},{"issue":"2","key":"2020081220292063100_i1543-2165-139-11-1431-b11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/IGC.0000000000000057","article-title":"Protection against squamous cell carcinoma and cervical adenocarcinoma afforded by cervical cytology screening: a cross-sectional study","volume":"24","author":"Vale","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"2020081220292063100_i1543-2165-139-11-1431-b12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"2","key":"2020081220292063100_i1543-2165-139-11-1431-b13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-1702(02)00187-9","article-title":"The viral etiology of cervical cancer","volume":"89","author":"Bosch","year":"2002","journal-title":"Virus Res"},{"issue":"3","key":"2020081220292063100_i1543-2165-139-11-1431-b14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3322\/caac.21139","article-title":"ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"Saslow","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"2020081220292063100_i1543-2165-139-11-1431-b15","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.2009.1569","article-title":"Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial","volume":"302","author":"Siebers","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"2020081220292063100_i1543-2165-139-11-1431-b16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.AOG.0000109426.82624.f8","article-title":"Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening","volume":"103","author":"Wright","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"13","key":"2020081220292063100_i1543-2165-139-11-1431-b17","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/cncr.28548","article-title":"Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009","volume":"120","author":"Rositch","year":"2014","journal-title":"Cancer"},{"key":"2020081220292063100_i1543-2165-139-11-1431-b18","article-title":"FDA approves first human papillomavirus test for primary cervical cancer screening","year":"2014","journal-title":"US Food and Drug Administration Web site"},{"key":"2020081220292063100_i1543-2165-139-11-1431-b19","article-title":"US Food and Drug Administration Web site","author":"Microbiology Devices Panel of the Medical Devices Advisory Committee: March 12, 2014 meeting","year":"2014"},{"issue":"1","key":"2020081220292063100_i1543-2165-139-11-1431-b20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-9378-7-26","article-title":"HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies","volume":"7","year":"2012","journal-title":"Infect Agents Cancer"},{"issue":"4","key":"2020081220292063100_i1543-2165-139-11-1431-b21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.27713","article-title":"Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe","volume":"132","author":"Tjalma","year":"2013","journal-title":"Int J Cancer"},{"issue":"11","key":"2020081220292063100_i1543-2165-139-11-1431-b22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020081220292063100_i1543-2165-139-11-1431-b23","article-title":"Cytopathology and more: evidence emerging for HPV-negative cervical cancer","volume":"28","author":"Zhao","year":"2014","journal-title":"CAP Today"},{"issue":"6","key":"2020081220292063100_i1543-2165-139-11-1431-b24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.5858\/arpa.2014-0202-OA","article-title":"Squamous cell carcinoma of the cervix: a cytology-histology-HPV correlation in clinical practice","volume":"139","author":"Miller","year":"2015","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"2020081220292063100_i1543-2165-139-11-1431-b25","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.5858\/arpa.2011-0609-OA","article-title":"Screening test results associated with cancer diagnosis in 287 women with cervical squamous cell carcinoma","volume":"136","author":"Li","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"2020081220292063100_i1543-2165-139-11-1431-b26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1471-0528.2008.01990.x","article-title":"Anshu, Gregory M, Gupta SS, Singh N. Invasive cervical cancer audit: a relative increase in interval cancers while coverage increased and incidence declined","volume":"116","author":"Herbert","year":"2009","journal-title":"BJOG"},{"key":"2020081220292063100_i1543-2165-139-11-1431-b27","unstructured":"College of American Pathologists cervicovaginal cytology benchmarks 2011. http:\/\/www.cap.org\/apps\/docs\/proficiency_testing\/CYP07600.pdf. AccessedFebruary42015."},{"key":"2020081220292063100_i1543-2165-139-11-1431-b28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jmv.2015","article-title":"Detection of high-risk HPV types by the hybrid capture 2 test","volume":"65","author":"Terry","year":"2001","journal-title":"J Med Virol"},{"issue":"4","key":"2020081220292063100_i1543-2165-139-11-1431-b29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.10717","article-title":"Measuring sensitivity in gynecologic cytology: a review","volume":"96","author":"Renshaw","year":"2002","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"2020081220292063100_i1543-2165-139-11-1431-b30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2307\/2530820","article-title":"Assessment of diagnostic tests when disease verification is subject to selection bias","volume":"39","author":"Begg","year":"1983","journal-title":"Biometrics"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/11\/1431\/1614186\/arpa_2014-0633-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/11\/1431\/1614186\/arpa_2014-0633-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:35:38Z","timestamp":1764790538000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/139\/11\/article-p1431.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,7]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,5,7]]},"published-print":{"date-parts":[[2015,11,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2014-0633-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,7]]}}}